OnCo

An immune checkpoint on exhausted T cells and on leukaemic stem cells; antibodies against it failed in lung cancer and MDS after strong preclinical promise. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Type I transmembrane receptor of the TIM family; ligand binding recruits BAT3 release and inhibits TCR signalling; on myeloid cells it regulates innate responses. Marks terminal exhaustion together with PD-1, LAG-3 and TIGIT.

Where it is found
  • Exhausted CD8 T cells in most solid tumours
  • Leukaemic stem cells in AML and MDS
  • Tumour-associated macrophages
Class: checkpoint · Gene: HAVCR2 · Facts checked 2026-09-08 · Target page

Elsewhere: identifiers and databases

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes that involve this target

Unaddressed routes →

The resistance atlas has no route that names this target.

Pathways where it is a node

Pathway-to-drug matrix →

No pathway diagram carries this target as a node.

Companion diagnostics and assays

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Key papers and the live literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"TIM-3" OR ABSTRACT:"TIM-3" OR TITLE:"HAVCR2" OR ABSTRACT:"HAVCR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIM-3, not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tim3.json. Licence CC BY 4.0.